Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Sarcoma 1Resectable Esophageal Cancer 1Pleural Mesothelial Neoplasm 1Neoplasm Metastasis 1Multiple Myeloma 1Melanoma 1Hematologic Neoplasms 1Colorectal Neoplasms 1

Interventions

Bevacizumab 120Fluorouracil 90Cetuximab 84Leucovorin 82Oxaliplatin 80pembrolizumab 70Irinotecan 66Nivolumab 46Capecitabine 43Specimen Handling 40regorafenib 30Folfox protocol 29trifluridine tipiracil drug combination 28Magnetic Resonance Spectroscopy 27Biopsy 27Panitumumab 26HMPL-013 26Standard of Care 25IFL protocol 21Gemcitabine 20Blood Specimen Collection 19tislelizumab 18atezolizumab 18Trifluridine 18Cisplatin 18balstilimab 16Colonoscopy 16Carboplatin 16encorafenib 15Paclitaxel 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Colorectal Neoplasms × Adjuvants, Immunologic × 1 year × Clear all
NCT06130826 2026-06-03

Immune Response Activation for the Treatment of Unresectable Metastatic Colorectal Cancer or CEA Positive Metastatic Breast Cancer

City of Hope Medical Center

Phase 1 Suspended
24 enrolled
BreastGastrointestinal

Breast Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡